Abstract

Analysis of Circulating Cell-Free DNA with QIAseq

Andrea Wijeweera, Sales Application Specialist, QIAGEN

Liquid biopsy harbours great potential towards improving health care especially in the area of diagnostics and disease monitoring. Advancement in technologies in the area of next generation sequencing now enable very low limits of detection from scarce amounts of these nucleic acids, including circulating cell-free tumor DNA and circulating tumor cells. When working with limited sample amounts, generating sensitive, accurate and reproducible results from cfDNA sample is the goal of any liquid biopsy assay approach. This talk will cover how QIAGEN can support researchers at every step of the liquid biopsy workflow, starting with sample collection and stabilization through to optimized NGS library preparation solutions for cfDNA.